Genmab A/S (GMAB) 2026 Q3 法說會逐字稿

完整原文

使用警語:中文譯文來源為 AI 翻譯,僅供參考,實際內容請以英文原文為主

  • Operator

  • Hello, and welcome to the Genmab third quarter 2026 financial results conference call. As a reminder, this conference call is being recorded. During this telephone conference [you might] be presented with forward-looking statements that include words such as believes, anticipates, plans or expects.

  • Actual results may differ materially, for example, as a result of delayed on the successful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results. unless this is required by law.

  • Today's presentation will also include comments on certain non-IFRS financial measures, which management uses to describe the company's baseline performance. And which supplements but do not substitute for the comparable IFRS measures. We encourage you to review our full financial statements and publicly filed reports and not to rely on any single financial measure.

  • Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going forward. Please refer to our website for more information on Genmab and our price policy.

  • I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.

  • Jan van de Winkel - President, Chief Executive Officer

  • Good to have you all with us, and welcome to Genmab's results call for the first nine months of 2026. Joining me are our Chief Financial Officer, Anthony Pagano; and our Chief Commercial Officer, Brad Bailey; and our Chief Medical Officer, Tahi Ahmadi; and Chief Development Officer, Judith Klimovsky, you will both join us for the Q&A.

  • As the operator said, we will be making forward-looking statements so please keep that in mind during the call. This has been a long lag stretch for Genmab, and I'm delighted to share it with you. Let's start with the numbers. Our total revenue was up 22% with growth coming from across our portfolio. We have continued to manage our investments thoughtfully and strategically, allowing us to grow our adjusted operating profit by 9%.

  • Growth and profitability together are certainly a sign of a healthy, high-quality business. But the product development news is what we got -- this is what has me most energized. October was a truly unprecedented month in our history with three milestone Phase 3 readouts all with the potential to change how patients are treated.

  • [Speed] strengths stand behind these results. Our expertise in antibody science and oncology, our ability to evaluate innovation and our speed of execution. You can see all three in these programs. We acquired Rina-S in May 2024 when it was a single Phase 1/2 trial, 2.5 years later, that's a positive Phase 3 and a broad Phase 3 program across the ovarian and endometrial cancers.

  • We acquired petosemtamab last December and less than 11 months after closing, it too has a positive Phase 3 and a growing Phase 3 program. And at EPKINLY, an antibody created by Genmab and co-developed with AbbVie has delivered three Phase 3 readouts this year.

  • We said these therapies had substantial promise and the Phase 3 data have now confirmed that. And in each case, the Phase 3 result is consistent with the Phase 2 data that led us there. Let me turn to the next slide to remind you of this remarkable Phase 3 data and what it means for us going forward. Last week, we held a goal summarizing the important Phase 3 data sets that we announced in October. You can listen to a replay of that call to our websites. So we'll keep this brief and focus on what it means for us.

  • First, at EPKINLY, the EPCORE DLBCL-2 trial, which not its progression-free survival and [go through] with a hazard ratio of 0.49 and demonstrated that EPKINLY has the potential to change our frontline diffuse last B-cell lymphoma is treated after more than two decades of our job as the standards. And expanding into online supports EPKINLY's potential to become core therapy and B-cell malignancies.

  • Second, Rina-S, call ambitions is Rina-S has to be the best first and broadest in class, the RAINFOL-02 trial, which met both its primary endpoint of progressive-free survival with a hashed ratio of 0.29 in the intent-to-treat population and the key secondary endpoint of overall survival supports that ambition and efficacy irrespective of fully receptor other expression level or previous mirvetuximab.

  • And platinum-resistant ovarian cancer is just our first potential launch with our established global presence and recurrent or metastatic cervical cancer, the breadth of Rina-S program across ovarian endometrial cancers positions us well to lead innovation in the [Gano] oncology section.

  • And third to petosemtamab. The LiGeR-HN1 trial, which met its dual endpoints of overall survival with a hazard ratio of 0.5 as well as objective response rates, HNSCC program in first-line head and neck cancer. This will be followed by our next milestone.

  • The LiGeR-HN2 trial in the second- and third-line setting, which we expect in the first quarter of 2027. And with two Phase 3 trials underway, we are already expanding into colorectal cancer, which is another area of significant unmet needs. And given the global capabilities that we have built, I have no doubt that we are well prepared to continue to maximize the potential of all three of these programs with successful commercialization if approved.

  • Now let me pass on to Brad to talk more about this and how we currently commercialize medicines that EPKINLY and Tivdak are doing in the market. Brad, the floor is yours.

  • Brad Bailey - Executive Vice President and Chief Commercial Officer

  • Thanks, Jan. Our proprietary medicines continue to perform extremely well with EPKINLY and Tivdak reaching more patients around the world. These results reflect the strength of our antibody science and effect execution by our teams to increase treatment adoption broaden access and expand the new markets.

  • Together with the late-stage progress Jan shared earlier, this performance puts us in a strong position to close out 2026 and deliver on our next phase of growth. EPKINLY is the most prescribed bispecific antibody in lymphoma globally, and we're building on that leadership.

  • Sales grew to $491 million in the first nine months representing a 47% increase year-over-year. In the US, EPKINLY continues to grow across indications and sites of care, particularly in the community for its differentiated dual indication profile is resonating with physicians. During the quarter, we increased the number of sites ordering at EPKINLY and expanded adoption among existing accounts with more than 97% of key customers now ordering from two or more sites.

  • We're especially pleased with the uptake of chemo-free, fixed duration of EPKINLY plus R2 in second-line FL, which is now considered the standard of care in this setting. This uptake is broadening physician experience with EPKINLY driving increased utilization across both FL and DLBCL and bringing bispecific based treatment to sites closer to where patients live.

  • Outside the US, EPKINLY continues to perform very well. In Japan, the launch of EPKINLY plus R2 second-line FL is off to an encouraging start, building on EPKINLY established presence in the market. Through our partner AbbVie, this combination has also approved in more than 40 countries creating opportunities to reach more eligible patients. For the rest of this year, our focus is on maximizing these opportunities, particularly in the US and Japan, where we book sales while preparing for anticipated launches in early lines of DLBCL as soon as next year.

  • Moving to Tivdak. Sales totaled $131 million in the first nine months, which is an increase of 9% year-over-year. This reflects strong, stable performance in the US and continued growth in our launch markets in Japan and Europe, driven by effective field execution and expanding site activation.

  • Tivdak is now approved and reimbursed in multiple countries with additional reimbursement discussions underway. This expansion is bringing Tivdak to more patients while strengthening the local market knowledge, customer relationships, and access capabilities that will help drive our success with Rina-S and petosemtamab in the future.

  • Looking ahead, our focus is on translating progress in our late-stage portfolio into well-executed launches and access for patients. For EPKINLY, first-line DLBCL represents a substantial opportunity to reach patients at the start of treatment and potentially advance the standard of care.

  • The broad physician network and treatment experience we're building today and EPKINLY's approved indications across sites of care serves as a strong foundation as we prepare to expand into earlier lines of the DLBCL. If approved, EPKINLY plus our job would significantly expand EPKINLY's role in lymphoma treatment and move us closer to our ambition of establishing EPKINLY as the core therapy in B-cell malignancies.

  • For Rina-S, the positive RAINFOL-02 results represent an important step forward for patients with platinum-resistant ovarian cancer who face limited options and poor outcomes. If approved, Rina-S would become our second medicine in gynecologic cancer and advanced our ambition to become the recognized leader in this space.

  • Our proven experience with Tivdak gives us an established understanding of gynecologic cancer care and long-standing relationships with physicians and care teams have set a strong foundation for our work with Rina-S in the future.

  • Lastly, as Jan shared, LiGeR-HN1 was the first positive Phase 3 trial in first-line head and neck cancer in nearly a decade. If approved, petosemtamab will broaden our solid tumor portfolio, and could offer an important new treatment option for patients in a setting where progress has been long overdue.

  • Over the last several years, we built a commercialization engine across key markets designed to scale with our portfolio and support the growth ahead. We're pairing deep antibody and oncology expertise with local market insights and data to different general medicines, secure broad access and drive successful launches. Our field teams bring these capabilities together with a highly coordinated and seamless engagement plan for care teams and customers supporting broad uptake and utilization.

  • As we close out 2026 and look towards 2027, we're in a strong position, driving growth from our approved medicines, advancing readiness for anticipated launches next year and turning the strength of our science into sustained growth and meaningful impact for more patients.

  • With that, I'll turn it over to Anthony to walk you through the financials.

  • Anthony Pagano - Chief Financial Officer, Executive Vice President

  • Thanks, Brad. The first nine months of 2026 demonstrated the continued strength of our business. with revenue growing 22% year-over-year. And I'd highlight two characteristics of our performance. First, the high level of the growth; and second, the broad-based nature of that growth.

  • Starting with the high growth. DARZALEX increased 19% year-over-year while worldwide EPKINLY net product sales increased 47%, reflecting continued commercial momentum and strong execution. Beyond these two brands, the remainder of our portfolio increased 30% year-over-year.

  • Turning to broad-based growth. Approximately half of our year-over-year revenue growth came from DARZALEX. Impressively, the other half was generated by EPKINLY and the remainder of our portfolio. Taken together, these results demonstrate that our business is becoming more diversified and more durable.

  • That evolution continues to strengthen the quality of our revenue base. And this strength provides us with the financial flexibility to continue investing behind our highest value growth opportunities. This includes launch readiness for EPKINLY, Rina-S and petosemtamab as well as the ability to broaden the development for both of our wholly owned programs.

  • As you know, we currently have nine ongoing Phase 3 trials for Rina-S and petosemtamab with more announced or in development. And even with this investment, we grew adjusted operating profit by 9%. So together, our results demonstrate that Genmab can increase investment while continuing to expand profitability.

  • Now let me briefly comment on tax. Our effective tax rate for the first nine months was 3.4%, primarily reflecting the ongoing integration of Merus and related recognition and utilization of deferred tax assets. As we've previously discussed, our effective tax rate may continue to fluctuate as those integration activities progress. We expect our effective tax rate will normalize over the next 12 to 18 months.

  • With that, let me turn to our 2026 financial guidance. We remain on track to achieve our 2026 guidance, which we are maintaining with strong revenue growth and strong profitability. We expect our revenue to be in the range of around $4.325 billion to $4.525 billion delivering a robust 19% growth at the midpoint. And it's EPKINLY and the continued momentum in our royalty portfolio that's driving that growth.

  • Given our performance through the first nine months, we now expect revenue to be in the upper part of that range. For operating expenses, our full year investment plan has not changed. So we still expect to be in a range of around $2.1 billion to $2.95 billion and we expect to be around that midpoint of $2.88 billion.

  • We expect Q4 OpEx to step up significantly because we have substantial activity planned in the fourth quarter including manufacturing, clinical development and launch readiness for Rina-S and petosemtamab. So I would caution against taking down your 2026 OpEx figures as a result of our first nine months.

  • Putting all this together, we're planning for adjusted operating profit in a range between $1.065 billion to $1.35 billion, with the midpoint of our guidance amounting to over $1.2 billion. With revenue in the upper part of the range and OpEx around the midpoint, we expect our operating profit to end above that midpoint.

  • Our guidance highlights our continued strategic discipline with revenue growth, funding targeted investments in petosemtamab, Rina-S, and launch readiness, all while maintaining strong profitability. Now finally, before I conclude, I'd like to take a minute to look ahead to 2027. While of course, our guidance will be given in February next year.

  • As I stand here today, 2027 consensus expectations for OpEx on Bloomberg and FactSet appear to be in a reasonable place, capturing our investment priorities. Importantly, we remain confident that Genmab will deliver strong profitability both in 2026 and continued growth in 2027.

  • So in summary, our performance in the first nine months of 2026 underscores our ability to produce high-quality revenue growth, advance our late-stage pipeline and maintain strong profitability through disciplined execution. Together, this positions us well to deliver sustained growth and long-term value creation.

  • Jan, back over to you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thank you, Anthony. This brings us to our final slides. It has already been a remarkable year for Genmab, both for our science and our financials. I can summarize this with three themes. The first is our sustained financial growth based on revenue from our portfolio, including significant contributions from EPKINLY.

  • The second is a high-potential late-stage pipeline where we have to have unprecedented Phase 3 readouts across EPKINLY, Rina-S and petosemtamab, setting up potential launches in 2027 and multibillion-dollar peak sales potential.

  • And finally, our disciplined capital allocation. We are investing in our high-impact late-stage programs with broad clinical development and launch readiness. All while sticking to our goal of gross leverage below 3 times by the end of next year.

  • In short, we have three high-quality late-stage programs, a broadening revenue base and more catalysts still to come. All of this gives us real momentum as we head into the next decade. So as we move forward to the end of the year, I could not be more energized about our future, both in 2027 and beyond.

  • That concludes our prepared remarks. Before we move to Q&A, I'm pleased to announce that we will hold our annual virtual R&D update and as data review event on December 16. Details will be available on our website and with over 20 accepted abstracts, including 6 oral presentations, we look forward to a lively event.

  • With that, thank you for listening. Operator, we are now ready for questions.

  • Operator

  • (Operator Instructions)

  • Benjamin Jackson, Jefferies.

  • Benjamin Jackson - Analyst

  • Thank you for the question, guys. Can I just start on the asset abstract for DLBCL, please? Just interested if there's any color you can add around what you're seeing or thinking about with regards to that OS favored ratio that obviously shows no detriment to the patients.

  • But is this something similar to what we saw in and around the DLBCL 1 trial, where we need to adjust for any come related deaths or so therapies. And how do you see this reading across to the first-line trial? Is it just a factor of the short or very short follow-up compared to the other trials that we see in the space? And is this something that ultimately you will need to show a statistically significant OS benefit in one of these two trials to be confirmatory across the board?

  • So any thoughts around the OS side of that as well? And also just as a follow-up on the safety side, slight increase in that trial in and around great [five] events? Is there any color you can add here? Is this correlated again? Or is something else at play? Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Ben. Very cleverly, I think, put three questions under the first one. The abstracts and then the safety one is an extra question. So I'll ask Tahi to start and then unit ship in you can add further color. Tahi?

  • Tahamtan Ahmadi - Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

  • Yeah, thank you, Jan. Thank you, Benjamin. There are probably five questions in there. So let me take them one at a time. As it relates to the US for the [for to eye]. I think you already alluded to. Meeting follow-up on that trial driven by the impressive [hazard] ratio on the PFS side, that triggers the readout was 10 months.

  • And if you just think about the cost comparison to [Pfizer] or the [glofi] [Genmab's] the follow-up there was more like towards 28 to 30 months. And so from that, you can just already appreciate that this is totally immature, so very few events.

  • As it relates to [COVID core] not necessary an issue anymore. These trials were on post the COVID phase. But of course, the availability of bi-specifics and cards. So the next available lymphoma treatment, thus to degree play a role. We're still very confident that the hesitation will continue to -- actually improve and actually show a benefit for EPKINLY. So we'll have to just wait for that formula.

  • As it relates to confirmatory trial, I think it's fair to say at this point. At the front line is a [petosemtamab] Phase 3 with an overwhelming positive PFS will function as our regulatory -- from a regulatory point also confirmatory trial. That was the second question that you had.

  • And the third one was on safety. You correctly noted that there were a few debt events on the Keytruda also on the control arm. But in the -- there is no isolated signal that is really motor factorial and it's a relatively small number of patients. So there are all kinds of different factors that play a role there.

  • So we stand behind the conclusion that really trying to show any new safety signals. And I think we will be better appreciated when the data is actually presented in its totality at [ASH]. I hope I touched on all of the questions.

  • Benjamin Jackson - Analyst

  • Yes, that's brilliant. Thank you very much.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Tahi. Thanks, Ben, for the question. Let's move to the next question.

  • Operator

  • Charlie Haywood, Bank of America.

  • Charlie Haywood - Analyst

  • Charlie Haywood, Bank of America. Thanks for taking my question. I have two, please. So the first one is just looking ahead to potential launches for these assets and how on Petospecifically, I think your prior commentary was $1 billion sales by 29%. And so I just wondered -- obviously, you've hit OS at interim, which I imagine was more of an upside scenario. So how has that informed confidence to reach that status by '29.

  • And then the second question, just on your two Phase 3 readout of your -- fileable readouts coming next year. So Petosecond, third line head and neck and then Rina-S second-line endometrial. I guess, both optically smaller ops than the recent anchor readouts you've had, but both broader halo potential for the assets you've got.

  • So OS benefit for Petoacross potentially first line, second line and third line and then Rina-S, ovarian and endometrial. So how do you view the commercial importance and potential halo effect of those two indications? Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Charlie. Brad, can you start off with both questions and then Anthony can potentially chip in also as it relates to the sales in '29 to provide further color if needed. Brad, maybe you can start.

  • Brad Bailey - Executive Vice President and Chief Commercial Officer

  • Thanks, Jan, and thank you for the question. And as we look ahead. Obviously, the oncology in general is a data-driven market and a very competitive market, but also extremely data-driven and we're confident in the data that we've seen to date for all the assets, as you mentioned across your questions.

  • And we're confident also in the capabilities we built at this point to bring our medicines to market. We really built our commercialization capabilities with all of this in mind over the last few years and certainly with this level of growth and expansion, looking to differentiate in these spaces.

  • We evaluate the markets with multiple sources overall and feel confident in the guidance we've provided thus far. And as we get into the data further with the presentations, as we've stated, upcoming Medical Congress next year, we'll be able to provide further color on that as we move forward.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Brad. Anthony, you want to give further color?

  • Anthony Pagano - Chief Financial Officer, Executive Vice President

  • Yeah, thanks, Charlie. Look, we've been super clear. We had high conviction I was zooming in on petosemtamab, we had high conviction in petosemtamab in October, we backed it up with the really super strong Phase 3 results, including the OS that you referenced.

  • So we stand fully behind the peak year sales estimate for petosemtamab at multibillion and we stand fully behind that $1 billion number for 2029. So I really feel like on the heels of this data, Charlie, we're well positioned here moving forward.

  • Charlie Haywood - Analyst

  • Great. Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Charlie.

  • Operator

  • Zain Ebrahim, JP Morgan.

  • Zain Ebrahim - Analyst

  • Hello, thanks for taking the questions. Zain Ebrahim, JP Morgan. Thanks from me as well. First question is on Petoand just how we should think about the duration of treatment that you're expecting to see from a modeling perspective.

  • I think in the Phase 2 you showed medium progression-free survival of about nine months, but based on the Phase 3 results, you're basically doubling overall survival. So could we see potentially longer duration of therapy than that progression-free survival nine-month point?

  • And my second question is on EPKINLY and how we should think about the pace of the rollout in first-line DLBCL and [second-line DLBCL] pending approval next year. Given the sense of the data at the 16th first line, could you see blockbuster sales for next year?

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Zain, for the questions. So maybe, Tahi, you can start with the Petoduration of response question. I don't know how much detail we can give here, but you can potentially give some perspective. And then, Brad, maybe you can talk about the launches and the rollout of EPCORE in the frontline DLBCL and further.

  • Tahamtan Ahmadi - Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

  • Yeah, thank you, Jan, and thank you, Zain, for the question. Of course, as I'm sure you understand, we're not going to be able to get at this point into a nuanced discussion around duration of treatment and any, like detailed discussion on the data until we have it in the public domain. I think it's important to step back though.

  • As you also were alluding to in your question to remind ourselves that from a pure odds ratio on response and then particularly on the OS hazard ratio. What we're looking at is really like a transformative study, and we're really excited to show. The fatality of the data in the context of the patient that we're enrolled. And then we can have these nuanced discussions around modeling, duration of treatment and these things.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Tahi. And Brad, maybe a bit on the rollout of EPKINLY in the different settings?

  • Brad Bailey - Executive Vice President and Chief Commercial Officer

  • Yeah, no, thanks. Thank you for the question. And we've said, for quite some time, the largest opportunities, obviously, as we move into earlier lines of therapy, specifically in frontline. And where the majority of the patients we know were treated in the community and intent of the treatment is curative.

  • The market is already moving, I think, as we know from R-CHOP to these R-CHOP combinations and also long stated that we believe bispecific can really build on this R-CHOP and emerge as the new standard, the top-line data at this point validate this position and the role EPKINLY plus R-CHOP can play. And we feel extremely confident again in the data for EPKINLY, we've built the capabilities all along to prepare for earlier lines of therapy as it relates to our infrastructure.

  • And we expect strong uptake at launch, primarily with academics and then certainly moving into the community as more sites gain experience, as we're already seeing, and a bit of a proof point with a second-line FL launch from around the same time last year. That's driven the primary part of our uptake thus far. So we expect strong uptake, and I look forward to sharing more as we move further.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thank you, Brad. As you said before, data is the currency in the oncology design, and what we hope is that we can actually present the data of the phone line study with [epcoritamab] quite quickly and show how fantastic that data is, so that launch will be even quicker once it's on the market.

  • Zain Ebrahim - Analyst

  • Very clear, thanks a lot.

  • Jan van de Winkel - President, Chief Executive Officer

  • Let's move to the next question, operator.

  • Operator

  • Romy O'Connor, Van Lanschot Kempen.

  • Romy O'Connor - Equity Analyst

  • Hi, this is Romy. Thank you for taking my questions. Maybe just following on to the previous one. So with the potential long treatment duration that we might see with pedacentamab, just wondering how you're thinking of the subcutaneous formulation and how advanced along is that?

  • And looking at the frontline DLBCL space, so following the positive data that we saw, how should we be thinking about the positioning of can we an R-CHOP against, for example, Pola-R-CHP? So do you anticipate more of a broad adoption or could treatment decisions be dependent on risk characteristics, for example? Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Romy. The first question can be on the circuit, maybe Tahi can start with that and then also handle the second question on the competition and the positioning versus Pola-R-CHP in frontline diffused as B-cell lymphoma. Tai, maybe you can start.

  • Tahamtan Ahmadi - Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

  • Yeah. So on the Petoquestions first. Look, we obviously started, I think the [be] with Halozyme was announced in middle, in the midst of the closure period of the acquisition of Merus. So we've been working on [SubQ]. We have always understood SubQ to be an important life cycle management component, and that's probably where we have to leave it at this point for a variety of reasons.

  • On the EPKINLY question, this question comes up a lot, and I think it's good to step back for a moment. So first off, R-CHOP EPKINLY has a ratio of 0.49. This word unprecedented that gets sometimes overused, but this is literally a trial at a scale of positivity that has not been seen in [diffuser-space] for a quarter of a century.

  • So what that also means, even without having a discussion on the nuanced data, is that when you have an effect size of that scale that probably will have an impact on a number of populations. So you can tell the difference between hazard ratio between [3:5] to [2:5] was non-existent, which basically means that the hazard ratio of 2 mimics the hazard ratio of the [3:5] population that in and of itself is already a significant differentiator.

  • And then there are other subgroup populations that you could think about as it relates to the original Pola-R-CHP dataset from POLARIX that led to the approval. So I think that's the first differentiator that's important. The second part that is important is while we're here today and we have a Phase 3, the [Glofi] Pola-R-CHP study is going to read out sometime in the future, I think it was just towards the end of next year.

  • So there is a significant time advantage and that's an important one. I think the third part that sometimes gets also not really appreciated is that. From the beginning, what we discussed, and Brad touched on this, the vast majority of these patients get treated in the community.

  • And in the community, our job is to stand out of care. That's something that physicians in the community are comfortable with for 25 years plus. SubQ administration is a differentiator for the community. Dual indications are going to differentiate in the community.

  • And so these things all are important aspects not to have two marketed products within a regimen plays a role in certain cost-conscious markets. And then the last part is if you actually look at the most recent ASH abstract that just got released by WASH. That's something that we also talked many years ago already.

  • There might be actually a ceiling that is determined by CD3/CD20 that is then determining how high you can go in the efficacy in terms of CR because there is really no difference between our shop Glofi and our CHP Glofi.

  • So I think that summarizes how we think about it. We feel very comfortable with the positioning of where we are, super excited to share this data as soon as we get the opportunity to, and then we'll more detailed conversations.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thank you, Tahi.

  • Romy O'Connor - Equity Analyst

  • Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Romy.

  • Operator

  • Asthika Goonewardene, Leerink.

  • Karina Rabayeva - Analyst

  • Hi, everyone. This is Karina for Astika. Congrats on all the data. I had a question for Rina-S. So sac-TMT, their Phase 3 data and the mutual showed meaningful PFS and OS benefit, but they also had 35% response rate and conceivable stomatitis. So with sac-TMT filed now, does Rina-S still have a shot at accelerate approval? And I have a follow-up.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thank you, Karina. Judith, can you take this question?

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Yeah, so thank you for the question. So, as for Rina-S in endometrial, we have a dual strategy. We started with a single arm, and in parallel, we opened a Phase 3 randomized study, so basically aligned with what we did with PROC. So, the -- more likely scenario now is that the filing will be based on the Phase 3 results.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Judith. That's very clear. Thanks, Karina.

  • Karina Rabayeva - Analyst

  • And I have a follow-up. For Rina, as the ovarian cancer data, they had, you guys showed a strong OS hazard ratio and there has been like a lot of buzz generated asthma. Are you seeing like any preliminary impact on patient recruitment to the other ongoing Phase 3 studies and also basket studies?

  • Jan van de Winkel - President, Chief Executive Officer

  • Judith, can you handle this one as well?

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Yeah/no, and thank you for the question. As you can appreciate, the unprecedented results of Rina in PROC are creating what we call a halo effect. So we expect recruitment on the other studies to be even more encouraged by these results being already making public.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Judith. Thanks, Karina.

  • Karina Rabayeva - Analyst

  • Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • And now we're [moving to the] next question. Thanks.

  • Operator

  • Gregory Renza, Truist.

  • Unidentified Participant

  • Hi, thanks so much for taking our question. This is [Support] on for Greg. Another one I've been asked. On the greater than $2 billion peaks out, how does that number split across platinum resistance, platinum sensitive and endometrial cancer? What setting drives most of the value? Thanks so much.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Greg, for the question. Anthony, you can handle this one for sure.

  • Anthony Pagano - Chief Financial Officer, Executive Vice President

  • Yeah, thanks, Greg. Really, I come back to the high conviction we've had in Rina-S and again, now we back this up with the Phase 3 data that was released in October and really showing that strong OS data. So really -- our convection is really backed up now in based upon this data.

  • So again, we stand fully behind that peak year sales estimate and just remind everybody for Rina-S, that's greater than $2 billion. That conviction comes from the data but also comes from the capabilities we've deliberately built. This [can] how we develop the medicines, how we commercialize them.

  • And you've seen again, remind everybody that strong execution with Tivdak and EPKINLY and that same engine is already doing the appropriate pre-launch work, particularly now zooming in on Rina-S. And really leveraging all of the capabilities we've also built out in the gynecological oncology space. I think we're very well positioned to deliver against that greater than $2 billion estimate for Rina-S.

  • [Gregory], at this stage, we're not breaking it down any further than that in terms of further breaking down ovarian or endometrial display. Really, I just have you focused on the capabilities in place. The data in place. For us to now deliver against that greater than $2 billion target for Rina-S.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Anthony. And as a reminder, Gregory, we also have tiles and lung cancer results in the gastrointestinal cancers with Rina, so it may have far broader potential than just ovarian and endometrial. Let's move to the next question, operator.

  • Operator

  • Rajan Sharma, Goldman Sachs.

  • Rajan Sharma - Analyst

  • Hi. Thanks for taking my questions. I've got two as well. First one, just on EPKINLY dynamics. It looks like sequential growth between 2Q and Q3. Was relatively flat. So could you just maybe talk about what you're seeing there and is that the run rate we should be expecting until the frontline approval comes through?

  • And then secondly, maybe just following up on a question from the call last week. Just now that you have the data in hand, how are you thinking about the shape of the topline and the bottom line of the company through the double X pattern expiration or -- sorry, your royalty expiration. Are you confident that the ability to grow through that, or at least be flat? Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Rajan. Very good questions. Brad, can you handle the first one? EPKINLY grow dynamics and how to think of that going forward? And then, Anthony, maybe you can start on the topline versus bottom line, and I can potentially jump in there as well. Brad?

  • Brad Bailey - Executive Vice President and Chief Commercial Officer

  • Yeah, thank you for the question. And we certainly continue to see post the second-line FL launch as well as removal of hospitalization, strong growth specifically in the US within EPKINLY. And as we look globally expecting, as mentioned, we just launched in Japan with second-line FL as well. And so I think you'll see that continue to -- we expect continued growth there also.

  • But we said all along. The earlier lines of therapy is where the value is and as we have just seen the data with frontline, looking to continue to build on this strength that we have with our infrastructure, both our field teams, our market access, patient service teams in the field are ready to deliver from that perspective as well. So I'll leave it there.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks for that. Maybe Anthony on the topline versus bottom line going forward?

  • Anthony Pagano - Chief Financial Officer, Executive Vice President

  • Yeah, happy to do so. And really, it's going to be reiterating some key messages we've been sharing with the markets here now for really the last year. It really starts with the strength, the quality and the high conviction that we had and continue to have really across EPKINLY, Rina-S and petosemtamab.

  • Again, now we back this up with this Phase 3 data here during the course of October. And again, we stand fully behind the peak sales estimates that we've previously communicated. And just to remind everybody, that's greater than $3 billion for EPKINLY, greater than $2 billion for Rina-S and multibillion for petosemtamab.

  • I would also then look to something we highlighted during our call today when I talked about the characteristics of the growth that we're seeing ex -- DARZALEX. EPKINLY up 47% compared to last year. So the rest of the portfolio up 30%. So putting that all together from a revenue perspective, we absolutely have the building blocks in place to see an overall very nice revenue growth trajectory here moving forward.

  • And then thinking about the investment and ultimately the bottom line, Rajan, I would really anchor you back to the important financial commitments that we've made to the market. Most recently when we acquired Merus in Q4 of last year or very late Q3.

  • And really three things that we said to you all. We said number one, we would deliver strong operating profit in 2026. Here, we're up year-to-date 9% on adjusted operating profit. We also said when we thought about 2027, we committed to deliver operating profit growth and to -- [deliver] to below 3 times gross leverage.

  • And based upon the strong performance of our brands, coupled with focused and disciplined investment, we are very well positioned to deliver these important 2027 financial commitments. So if you zoom out, Rajan, it's really thinking we have it from a revenue perspective, the building blocks in place. Very high-quality data we've seen here in October and that real focus in leveraging that revenue to the extent possible to drive profits for Genmab.

  • So we're not in a position today to give you any real specific medium-term guidance, but you really should take away from this that the building blocks are really in place here at Genmab from both a product perspective as well as a capability perspective.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Anthony. I think very little to add. It comes down to execution. Execution here, Rajan, and that's what we are pretty good at.

  • Operator

  • Xian Deng, UBS.

  • Xian Deng - Analyst

  • Hi, thank you very much for taking my questions. Two, please, one on petosemtamab in colorectal. So just looking at the ESMO data you presented. So just wondering the OR, of course, looks very high, but the current standard of care in this particular -- sorry, in the frontline setting also looks pretty high. And my understanding is the duration is what really matters.

  • So just wondering, given the public data, we've seen it's relatively early stage, and you've already started Phase 3. So just wondering, what are your thoughts in terms of in the duration and especially considering an event map? It's actually a lot ahead in terms of timeline, so just wondering your confidence on duration, especially also versus [petosemtamab] on that. So that's the first question.

  • Second one is Rina-S, so you are announcing the Phase 3 trial in frontline pMMR endometrial. So just wondering, if that, trying to replace chemo induction or multiple to add during maintenance. And sorry, this is a long second question.

  • So it's a broader one on Rina-S. Is that you are also starting Stage 3 on maintenance on key fault as well as induction in PSOC. So historically, the maintenance in those settings, whether it's endometrial or ovarian, it tends to be monotherapy and no chemo.

  • I'm just wondering, given the toxicity of chemo, but then of course, this is ADC. So just wondering what are your overall thoughts? On potentially using ADCs in maintenance setting. I'm asking because whether you can use it in maintenance setting actually matters a lot in Q2. So thank you very much.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Xian. Very good question. So first one, I think, can be handled by Tahi, and then Judith, you can take the Rina-S question, and then Tahi can potentially step in there as well.

  • Tahamtan Ahmadi - Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

  • Yeah, let me just start with a Petoquestion, and then between [Judith] and me. We can certainly also answer the questions. Let's start with the colorectal. Yeah. So -- I mean, you're absolutely right that the follow-up for the frontline data set that we presented was relatively short. I think it was five months.

  • But in the end, there are two data sets. There's also a second-line data set with a slightly longer follow-up, which is the same combination with chemotherapy for [FOLFOX] or for [FOLFIRI]. And so you can, to a degree, extrapolate from the second-line durability that is already, I think, better appreciated to the front-line durability.

  • And in the end, durability is a function of the mechanism, of course, the safety profile and the treatment duration and, of course, the sensitivity of the disease. And so this is at least how we think about it. So we looked at these data sets not in complete isolation, they also inform each other.

  • And if you take them in totality, both with point estimates, higher response rate that have been described than any data set that has described before, response rate in that data set in front line, obviously in the left side. And then in the second line in the totality of patients, these data points give us confidence. And then the durability that we've seen on the second line of [Merus] confirms that conviction.

  • And then, of course, by now, I think we are broadly speaking a pretty robust understanding of the safety of petosemtamab. And that's particularly relevant also as you start getting into these thought exercises and comparing it to Amivantamab. And I think we've talked about this also in the last call.

  • There is a very clear distinction in the safety profile and the tolerability of Petoversus Amivantamab. In terms of the system organ class, obviously, as an EGFR class, there are skin-related toxicities. But the numerical, the degree greater and higher, and the complexity and even like the locality of the affected skin areas is drastically different between these two assets.

  • And so if you then compare the safety that we have generated now repeatedly and that also is in the Phase 3 obviously, to the available datasets with Ami and then you know that Amivantamab achieves that safety profile with a very complex and involved mitigation strategy. And I think it's pretty obvious that there's a massive differentiation on safety and that definitely in our mind translates into durability.

  • So I think that's my answer on the colorectal, so we feel super excited about colorectal. And I think the data that we presented just at ESMO underwrites the excitement that, of course, already had motivated us to start these two Phase 3s.

  • And then I would say this written -- this would not be the first Phase 3 that we have started after the competition that read out before the competition. And then I give it to Judith on the Rina questions.

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Yeah, so thank you for your questions. For Rina, the -- is the endometrial cancer study that is in the public domain? Is the Phase 3 in the second third line? The first line is planned, so we haven't provided specifics about the design or comparator. But as you well alluded to, the standard of care is induction, chemo plus IO, followed by maintenance IO. So we haven't shared the specifics of the trial, but stay tuned, we'll be shortly posted.

  • With regard to PSOC, we have a dual strategy, in fact, like triple strategy. So in PSOC second, third line, we have two studies, Study 04 and 07, one is maintenance post Darzalex chemo plus minus BEV, and the other one is -- what we call replacement strategy.

  • And we have the first line piece of posted recently in [Clinicaltrials.gov], which is not piece of a first line maintenance, which is doublet chemo followed by BEV versus double chemo photo divest plus Rina. So basically what we are doing is covering all the aspect to potentially unleash the full potential of Rina in the whole spectrum of the disease.

  • Tahi, do you want to add anything?

  • Tahamtan Ahmadi - Executive Vice President, Chief Medical Officer, Head of Experimental Medicines

  • Well, the only other thing is like in your question, you alluded to the idea of whether or not an ADC at all is a maintenance drug. And I think there -- again, nuances matter. I think we've talked a lot about what we consider to be a differentiation for Rina-S, and that is -- that -- it is mainly [hema] toxicity.

  • They are mainly restricted to the first or second cycle and then thereafter. It is actually a very well tolerated drug with an extremely low discontinuation rate. And then if you have a drug that has a safety profile that is truly tolerable, meaning it doesn't have this discontinuation due to high toxicity, neurotoxicity, interstitial lung disease, or any other form of cumulative toxicity. Then -- it is actually indeed a very good maintenance drug.

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • And we presented data on Rina BEV last year that speaks about that, the good tolerability in terms of patients staying on both drugs, BEV and Rina, for a long period of time.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thank you, Xian. Thank you, Judith and Tahi. I think it's really a very good response to the question from [Cheiron]. Let's move to the next question, operator.

  • Operator

  • Yaron Werber, TD Security.

  • Yaron Werber - Analyst

  • Great. Thank you so much. So I have a couple of questions. The first one is, [Anpito], would you file based on the first-line survival data that you just got or would you wait to file and include the second-line survival data, which we're expecting early next year?

  • And then secondly, and I think it's maybe a Xian question relative to what was asked before, I think when many of us look at the guidance now, $3 billion and higher for EPKINLY, $2 billion for Rina-S, and $1 billion for Peto, they all look fairly conservative. What would it take to update them? Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Yaron, for the question. So the first one, Judith and Tahi can take that one. And maybe Judith and then Anthony, you can give more perspective on the guidance.

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Yeah, so as we guided the street, when we share the topline results of [LiGeR-01], we are actively planning engaging with health authorities for the potential filing based on the results that we already communicated.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Judith. Anthony?

  • Anthony Pagano - Chief Financial Officer, Executive Vice President

  • Yeah, Yaron. And I just at this stage, we're going to stand fully behind the previous peak year sales estimates for the three brands. Again, reminder, it's greater than $3 billion for EPKINLY, greater than $2 billion for Rina-S.

  • I just want to clarify, I think you said $1 billion for petosemtamab. For petosemtamab, it's multibillion. We had strong conviction in these estimates coming into the readouts that we saw in October, and we continue to have that high conviction, and that's where I'm going to leave it for now.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks. Anthony. Thanks, Yaron for the two questions.

  • Operator

  • Victor Floc'h, BNP Paribas.

  • Victor Floc'h - Analyst

  • Hi, thanks so much for taking my question. Maybe just first one, a quick follow-up on the [subcute] combination. I noticed that you've added a new cohort to the Phase 2 co-director study. I'm just wondering whether this would be -- whether it would be enough to support a subcute finding across indication, or would you still need a dedicated bridging study?

  • And the follow-up is on the commercial opportunity for Peto. I was wondering whether the substitute could become as important as a driver for Petothat it has been for DARZALEX and whether the substitute launch is already factored in your ambition to reach at least $1 billion in sales by 2029?

  • And finally, more broadly, how does [Keytruda] expected loss of exclusivity towards the end of the decade shape your long-term expectation for Peto? Thank you very much.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Victor, for the questions. Maybe Judith, you can actually take the Petosubcute question.

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Yeah, so I -- yeah.

  • Jan van de Winkel - President, Chief Executive Officer

  • And Brad relate to --

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Thank you. So, I would echo what Tahi answered with regard to the Petosubcutaneous. We already mentioned the partnership with Halozyme to start the development of the subcutaneous. It's part of our life cycle management. So, it's premature to highlight details of the specific plans that we will follow.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Judith. And Brad, maybe the [FASPRO] as a driver, like [DARZALEX FASPRO] was driving the DARZALEX sales, maybe you can say a bit, give a bit of perspective there.

  • Brad Bailey - Executive Vice President and Chief Commercial Officer

  • Yeah, no, thank you for the question. And as already mentioned, the LiGeR-HN1 data shows the potential for, petosemtamab to be both first and best in class in frontline head and neck.

  • And we're confident in this potentially practice changing data that we've just looked into and shared, and any innovations, certainly, or updates would be assessed in the future, and we'll certainly update those as we move forward. But, again, an extremely area of high-end met need right now, and I'm very confident in the data we presented at this point.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Brad. Thanks, Victor, for the questions. Let's move on to the next one.

  • Operator

  • Sean Laaman, Morgan Stanley.

  • Sean Laaman - Analyst

  • Hello, everyone. Congrats on the results. Thanks for taking my number and hope everyone's well. Two quick ones. First of all, strategic, given the significant strengthening you've observed at the late-stages pipeline. And has your appetite for external business development changed or has execution on internal assets now the highest return use of capital is the first one?

  • And the second one is just on the CRC programs, what milestones should we expect over, say, next 12 to 24 months and given where you could position this in CRC, particularly with the differentiated safety profile you're pointing to? And could the opportunity outsize what you observe or expect in head and neck? Thank you.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thanks, Sean. I will take the first one myself and then the CRC questions Juthid can handle. So [BD], we are very active, Sean, in looking at interactions with other companies for potential combinations of other drugs. We already announced the insight partnership recently, there will be more to come.

  • But we are currently focusing on really maximizing the potential of our late-stage programs. Two of the three have been taken in via BD acquisitions, but we also are working very strongly on our organic pipeline. We don't talk a lot about it because we want you to focus on the late-stage programs.

  • But this year, we moved already four new programs, antibody-based programs into the clinic from our own pipeline, two bispecific, two ADC. And at least two more programs will be moved into the clinic between now and the end of the year.

  • So we are very actively working on an organic pipeline, but it will be balanced, but right now the focus is clearly on maximizing the potential of the late stage what I call winning program, Sean, and also, we have -- also -- of course, a commitment in addition to this expansion of the programs to also lower the leverage.

  • Basically, by end of next year to less than three-fold growth leverage which we have focused on but we have a very active BD team to really bring the outside landscape into great perspective for us, so that we can strike again if needed in the future. And then maybe Judith you can talk about the colorectal cancer settings.

  • Judith Klimovsky - Executive Vice President & Chief Development Officer

  • Yeah, so, thank you. So, unfortunately, [mCRC] is a high unmet medical need and a larger opportunity potentially commercially than head and neck. So, in first-line care as well, the treatment paradigm is an EGFR antibody, usually cetuximab or [panitumumab], plus for FOLFOX or for CD. Unfortunately, the median PFS is only 12 months, and median overall survival is around two years.

  • In the second line, the unmet medical need is even more compelling, with best treatment in [Darzalex] while with cetuximab, panitumumab or any other EGFR plus chemo. The response rate is only 30%, 40%, median PFS six months and median survival of one-year.

  • So comparing unmet medical need whereas we highlighted -- as I highlighted in ESMO, we showed very strong encouraging although still early preliminary data. So we expect to have longer follow-up of this data set, which is pretty good for a Phase 2 proof of concept, and we will communicate this when the data is more mature.

  • Jan van de Winkel - President, Chief Executive Officer

  • Thank you, Judith. Thanks, Sean for the question. Thank you. I think this will end our Q&A. So thank you all for your questions and for being with us today. And as always, if you have additional questions, please reach out to our Investor Relations team.

  • Operator

  • This concludes this conference call. Thank you for participating. You may now all disconnect. Have a nice day.